Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
idelalisib + rituximab
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Idelalisib + rituximab is a combination therapy used primarily for the treatment of relapsed chronic lymphocytic leukemia (CLL). Idelalisib is an oral small molecule inhibitor that selectively targets the delta isoform of phosphoinositide 3-kinase (PI3Kδ), a key enzyme in B-cell receptor signaling pathways. By inhibiting PI3Kδ, idelalisib disrupts malignant B-cell proliferation and survival. Rituximab is a monoclonal antibody that binds to CD20 on the surface of B-cells, marking them for destruction by the immune system. This combination exploits both targeted inhibition of intracellular signaling and immune-mediated cell killing to control CLL progression[1][2][5][6].
- Brand names
- ZydeligRituxan
- Other names
- R-Idelalisib
02
Targets
PIK3CD (Phosphatidylinositol 3-kinase delta)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on idelalisib + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on idelalisib + rituximab.